Researchers have launched new multi-modal screening pathways in the UK to help detect Alzheimer’s disease earlier, even before symptoms appear. The service, called CognitionCheck, combines advanced imaging, artificial intelligence, and blood tests to provide a comprehensive assessment of cognitive health. This is particularly important for adults aged 50 and older, as studies show that four out of five people want to know if they have the disease before they experience any noticeable decline.

This new approach could significantly improve your chances of maintaining cognitive health as you age. By identifying Alzheimer’s pathology early, you may be able to access new treatments that slow the progression of the disease. The CognitionCheck pathway costs £1,295 ($1,736) and includes a structural MRI scan, AI-driven cognitive testing, and blood biomarker analysis, which can detect early signs of Alzheimer’s even in those with mild memory complaints.

While the CognitionCheck service is a step forward, it highlights a larger issue: the need for more accessible testing methods. Traditional blood tests require visits to clinics, which can be a barrier for many. However, a recent study has shown that at-home blood sampling using a simple fingertip prick can provide reliable results comparable to traditional methods. This could pave the way for decentralized testing, making it easier for people to monitor their cognitive health from home, thus expanding access to necessary diagnostics as the population ages.

As these technologies evolve, they may lead to a future where monitoring cognitive health is as easy as taking a blood sample at home, allowing for better prevention and management of Alzheimer’s disease.

Source: longevity.technology